REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
19/01/2026
Voltar para busca
Dado oficial do USPTO
SIEN-NET
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
26
Atualização mais recente
20/01/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
08/11/2019
Data de registro
19/01/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/01/2021
Última transação
20/01/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
83
Localização do titular
AU
Examinador
LAM,HAI-LY HUYNH
Unidade examinadora
N10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Sienna Cancer Diagnostics Ltd
Representantes
Charles G. Zug Nelson Mullins Riley & Scarborough LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations and substances for the treatment and/or diagnosis of cancer and infectious diseases; biotechnologically-formed enzyme preparations for medical purposes; medicinal preparations for the treatment of cancer and infectious diseases; monoclonal antibodies for therapeutic purposes; products containing antibodies for use in medicinediagnostic kits consisting primarily of monoclonal antibodies used in the capture of specific biological markers for use in disease testing; proteins for binding antibodies for medical use; proteins for detecting antibodies for medical use; reagents for medical usefor use in the development of monoclonal antibodies; diagnostic biomarker reagents for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancerviralbacterial infection; vaccines for human use; diagnostic preparations and reagents for medical purposes; vaccine adjuvants; diagnostic preparationsreagentssubstances for medical purposes; diagnostic products and testing materials for medical purposesdiagnostic kits consisting primarily of monoclonal antibodiesbuffersreagents for use in capturing and purifying specific biological markers for use in disease testing; reagents for use in diagnostic tests for medical purposes; medical diagnostic reagents for capturing and purifying specific biological markers that can be utilised in therapeutics or diagnostics; cells for growing recombinant human protein for medical purposes; recombinant DNA technology proteins for medical use; biological reagents for use in molecular biologyreagents for medical use for capturing and purifying specific biological markers that contain nucleic acid; antibodies that are specifically able to bind and capture specific biological markers for medical purposes; antibody fragments that are specifically able to bind and capture specific biological markers for medical purposes; antibody conjugates that are specifically able to bind and capture specific biological markers for medical purposes; pharmaceutical preparations for the treatmentreconstruction and repair of antibodies; immunological antibodies for medical use; monoclonal antibodies for medical diagnostic use; monoclonal antibodies for medical use
Publicações
Histórico de despachos e eventos da marca no USPTO.
26 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
16/05/2021
FICS
FINAL DISPOSITION NOTICE SENT TO IB
23/04/2021
FIMP
FINAL DISPOSITION PROCESSED
23/04/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
19/04/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
29/01/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
19/01/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/11/2020
PUBO
PUBLISHED FOR OPPOSITION
03/11/2020
GPNX
NOTIFICATION PROCESSED BY IB
02/11/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
14/10/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
14/10/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
14/10/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
24/09/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/09/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/09/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/09/2020
RFNT
REFUSAL PROCESSED BY IB
27/03/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/03/2020
RFRR
REFUSAL PROCESSED BY MPU
09/03/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
19/02/2020
CNRT
NON-FINAL ACTION WRITTEN
18/02/2020
DOCK
ASSIGNED TO EXAMINER
12/02/2020
MAFR
APPLICATION FILING RECEIPT MAILED
27/12/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
23/12/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
19/12/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SIEN-NET ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.